534 research outputs found
Don\u27t Give Me Diamonds, All I Want Is You
https://digitalcommons.library.umaine.edu/mmb-vp/1326/thumbnail.jp
I\u27m trying so hard to forget you
https://digitalcommons.library.umaine.edu/mmb-vp/6029/thumbnail.jp
One, Two, Three, Boys, : Over The Top We Go
https://digitalcommons.library.umaine.edu/mmb-vp/4283/thumbnail.jp
I\u27m trying so hard to forget you
https://digitalcommons.library.umaine.edu/mmb-vp/1570/thumbnail.jp
After \u27While
https://digitalcommons.library.umaine.edu/mmb-vp/1038/thumbnail.jp
Fly Away Birdie To Heaven
https://digitalcommons.library.umaine.edu/mmb-vp/1437/thumbnail.jp
Break the News to Mother
https://digitalcommons.library.umaine.edu/mmb-vp/1119/thumbnail.jp
Belle of the Ball
https://digitalcommons.library.umaine.edu/mmb-vp/5144/thumbnail.jp
The virtual heart as a platform for screening drug cardiotoxicity
To predict the safety of a drug at an early stage in its development is a major challenge as there is a lack of in vitro heart models that correlate data from preclinical toxicity screening assays with clinical results. A biophysically detailed computer model of the heart, the virtual heart, provides a powerful tool for simulating drug–ion channel interactions and cardiac functions during normal and disease conditions and, therefore, provides a powerful platform for drug cardiotoxicity screening. In this article, we first review recent progress in the development of theory on drug–ion channel interactions and mathematical modelling. Then we propose a family of biomarkers that can quantitatively characterize the actions of a drug on the electrical activity of the heart at multi‐physical scales including cellular and tissue levels. We also conducted some simulations to demonstrate the application of the virtual heart to assess the pro‐arrhythmic effects of cisapride and amiodarone. Using the model we investigated the mechanisms responsible for the differences between the two drugs on pro‐arrhythmogenesis, even though both prolong the QT interval of ECGs. Several challenges for further development of a virtual heart as a platform for screening drug cardiotoxicity are discussed
- …